Wealth Enhancement Advisory Services
ADCT icon

Wealth Enhancement Advisory Services’s ADC Therapeutics ADCT Stock Holding History

Wealth Enhancement Advisory Services’s Portfolio ADCT Stock Details ADCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$25K Buy
19,343
+5,113
+36% +$14.9K ﹤0.01% 4010
2026
Q1 		$53.8K Buy
14,230
+2,508
+21% +$9.89K ﹤0.01% 3420
2025
Q4 		$41.5K Buy
11,722
+125
+1% +$507 ﹤0.01% 3538
2025
Q3 		$50K Buy
11,597
+365
+3% +$1.15K ﹤0.01% 3429
2025
Q2 		$32K Sell
11,232
-3,758
-25% -$7.91K ﹤0.01% 3263
2025
Q1 		$21.1K Buy
+14,990
New +$25.5K ﹤0.01% 2913

Other funds holding ADCT

RWP
Revolve Wealth Partners Hackensack, New Jersey $965M AUM 22.88% 1-Year Est. Return
DIM
DLK Investment Management Solana Beach, California $235M AUM 12.41% 1-Year Est. Return
SCM
Saxony Capital Management St. Louis, Missouri $218M AUM 24.57% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return

Wealth Enhancement Advisory Services's ADCT Position: Q2 2026 in Review

Wealth Enhancement Advisory Services increased its ADC Therapeutics (ADCT) stake by 36% in Q2 2026, buying an estimated $14.9K and bringing the position to 19,343 shares worth $25K. The position accounts for ﹤0.01% of the portfolio, ranked #4010.

Wealth Enhancement Advisory Services first reported a position in ADCT in Q1 2025 and has held it in 6 quarters since. The position peaked at $53.8K in Q1 2026. 6 funds tracked by Wall St. Rank hold ADCT as of Q2 2026.

  • Wealth Enhancement Advisory Services held 19,343 shares of ADC Therapeutics worth $25K as of Q2 2026.
  • Wealth Enhancement Advisory Services bought 5,113 ADC Therapeutics shares in Q2 2026, an estimated $14.9K.
  • ADC Therapeutics made up ﹤0.01% of Wealth Enhancement Advisory Services's portfolio in Q2 2026, its #4010 holding.
  • Wealth Enhancement Advisory Services first reported a position in ADC Therapeutics in Q1 2025 and has held it in 6 quarters since.
  • Wealth Enhancement Advisory Services's ADC Therapeutics position peaked at $53.8K in Q1 2026.
  • 6 funds tracked by Wall St. Rank held ADC Therapeutics as of Q2 2026.

Based on Wealth Enhancement Advisory Services's 13F filing for Q2 2026, filed 15 Jul 2026.